You are here
Photodynamic therapy (PDT) utilises a specific laser frequency to damage or destroy cancer cells. The cancer cells are primed with a photosensitising drug to react to the laser wavelength frequency, while normal cells in the surrounding environment remain un-reactive and unharmed.
The National Institute of Integrative Medicine has undertaken a clinical trial into Sono-photodynamic therapy and a study on New Generation PDT light delivery technology.
Please be aware that NIIM is not accepting participants for either of the research projects.
New Generation Photodynamic Therapy (NGPDT)
PDT as a method of cancer treatment has been used exclusively in the treatment of superficial tumours due to the limitations of the laser light to penetrate into deep tissues.
The NIIM NGPDT clinical trial will investigate the efficacy of New Generation PDT light delivery technology in conjunction with a newly developed photosensitising agent in penetrating to cancers of deep tissues. This one year pilot study will indicate potential direction for future research in NGPDT.
Sono-PDT for Prostate Cancer
Sono-photodynamic therapy (SPDT) utilises both sound and light frequencies to damage and destroy tumors. A sensitising agent primes the tumor cells to specific frequencies, but has no effect on regular, healthy cells.
Administration of SPDT through localised and whole body routes then causes a reaction within the sensitised tumor cells, which results in formation of reactive oxygen species (ROS), destroying the tumor mass. The therapy produces minimal side effects and does not damage surrounding tissues. The SPDT clinical trial treats men with prostate cancer who have not responded to previous treatment, and may, in the future offer a further treatment option for patients who have failed other therapies.